CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases. Our team has over 25 years’ experience in oncology and molecular cell biology and are using our expertise and experience in these areas to develop value-based, first-in-class medications that are scalable to address global unmet medical needs in the oncology and inflammatory disease markets
CV6 Therapeutics is developing value-based, first-in-class medications that are scalable to address global unmet medical needs in the oncology and inflammatory disease markets
Belfast, UK, 10 May 2024 – CV6 Therapeutics (‘CV6’) is a clinical-stage drug development company targeting Uracil-DNA biology to transform the treatment of cancer and inflammatory diseases. CV6 will be presenting details of their ongoing CV6-168 Phase 1a clinical trial at the 2024 ASCO Annual Meeting to be held at McCormick Pace in Chicago, USA on […]
Find Out More